← Back to Clinical Trials
Recruiting NCT04800484

NCT04800484 The Effects of AFO Heel Height and Stiffness on Gait

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04800484
Status Recruiting
Phase
Sponsor University of Iowa
Condition Musculoskeletal Injury
Study Type INTERVENTIONAL
Enrollment 40 participants
Start Date 2019-11-07
Primary Completion 2027-01-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type INTERVENTIONAL
Interventions
Tall SoftTall FirmShort Soft

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 40 participants in total. It began in 2019-11-07 with a primary completion date of 2027-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The proposed study evaluates the effect of ankle foot orthosis (AFO) heel height and stiffness on the forces and motion of the lower limb during over-ground walking in individuals who use an AFO for daily walking. Previous studies suggest that heel height and stiffness effect limb loading, but these data and the analysis techniques applied are limited. In this study, heel cushions with different height and stiffness's (4 conditions) will be placed in participants shoes and they will walk at controlled and self-selected speeds. Participants will also walk with their AFO as configured prior to enrollment, and with no AFO if possible. The proposed study will provide evidence that can be used by clinicians and researchers to align braces that most effectively improve function during every-day walking.

Eligibility Criteria

GROUP 1 Patient Inclusion criteria * Ages: 18-70 * Daily AFO use to address unilateral, below knee functional deficits that result from limb injury or musculoskeletal disease (e.g. fracture, muscle and/or nerve injury, ankle arthritis) * Greater than 2 weeks using their current AFO * Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.) * Ability to walk at a slow to moderate pace * AFO fits into traditional footwear * Able to read and write in English and provide written informed consent GROUP 1 Patient Exclusion criteria * Pain \> 6/10 while walking during testing or an increase in pain during testing of \> 2/10. * Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity). * Disorder or disease that affects peripheral nerve function (e.g. diabetes, Charcot Marie Tooth). * Limited contralateral lower limb function due to injury or neurological/musculoskeletal disorder. * Use of a hinged/articulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist/stop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot. * Use of an AFO that crosses the knee (Knee brace) * Insufficient space in shoe to accommodate the tallest heel wedge and their AFO * Visual or hearing impairments that limit walking ability or could limit the ability to comply with instructions given during testing * Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study. * Body Mass index \> 40. GROUP 2 Patient Inclusion Criteria * Ages: 18-70 * Daily AFO use to address below knee functional deficits that result from disease involving the peripheral nervous system (e.g. Charcot Marie Tooth, Multiple Sclerosis, diabetes) * Greater than 2 weeks using their current AFO (unilateral or bilateral) * Ability to walk 50 feet without use of an assistive device (Cane, crutch, etc.) * AFO fits into traditional footwear * Ability to walk at a slow to moderate pace * Able to read and write in English and provide written informed consent GROUP 2 Patient Exclusion Criteria * Pain \> 6/10 while walking or an increase in pain during testing of \> 2/10 * Central Nervous System disorder or disease (e.g. Stroke, Cerebral Palsy, Spinal Cord Injury, or other conditions that result in lower limb spasticity) * Limited function due to limb injury (e.g. fracture, muscle and/or nerve injury) * Use of a hinged/articulating AFO (e.g. Plantar flexion stop, Dorsiflexion assist/stop, free motion), Charcot Restraint Orthotic Walker (CROW) boot, AFOs that restrict all motion in the ankle and foot. * Use of an AFO that crosses the knee (Knee brace) * Insufficient space in shoe to accommodate the tallest heel wedge and their AFO * Visual or hearing impairment that limit walking ability or limit the ability to comply with instructions given during testing * Pregnancy - Per participant self-report. Due the expected small number of pregnant individuals, and resulting inability to account for its effect on resulting outcomes participants will be withdrawn from the study * Body Mass index \> 40.

Contact & Investigator

Central Contact

Jason M Wilken, PT, PhD

✉ jason-wilken@uiowa.edu

📞 319-335-6857

Principal Investigator

Jason M Wilken, PT, PhD

PRINCIPAL INVESTIGATOR

University of Iowa

Frequently Asked Questions

Who can join the NCT04800484 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Musculoskeletal Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04800484 currently recruiting?

Yes, NCT04800484 is actively recruiting participants. Contact the research team at jason-wilken@uiowa.edu for enrollment information.

Where is the NCT04800484 trial being conducted?

This trial is being conducted at Iowa City, United States.

Who is sponsoring the NCT04800484 clinical trial?

NCT04800484 is sponsored by University of Iowa. The principal investigator is Jason M Wilken, PT, PhD at University of Iowa. The trial plans to enroll 40 participants.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology